AbbVie director granted 1,118 RSUs

WADDELL FREDERICK H reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

WADDELL FREDERICK H reported acquisition or exercise transactions in this Form 4 filing.

AbbVie Inc. director Frederick H. Waddell received an equity grant of 1,118 shares of AbbVie common stock in the form of restricted stock units. The award was granted at no cash cost to him as part of AbbVie’s incentive stock program.

The restricted stock units will be settled on a one-to-one basis in AbbVie shares upon the earlier of his separation from service, death, or a change in control as defined in the program. Following this grant, he directly holds 30,076 AbbVie shares.

Insider Trade Summary

Grant/Award: 1,118 shares

Grant/Award 1 txn

Insider WADDELL FREDERICK H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.01 par value	1,118	$0.00	$0.00

Holdings After Transaction: Common Stock, $0.01 par value — 30,076 shares (Direct)

Footnotes (1)

1. F1. These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Key Figures

RSU grant size: 1,118 shares Grant price per share: $0.0000 per share Shares after transaction: 30,076 shares +2 more

5 metrics

RSU grant size 1,118 shares Restricted stock units awarded to director on 2026-05-08

Grant price per share $0.0000 per share Equity award granted at no cash cost

Shares after transaction 30,076 shares Direct AbbVie holdings following RSU grant

Transaction code A Grant, award, or other acquisition of non-derivative securities

Transaction date 2026-05-08 Date of restricted stock unit grant

Key Terms

restricted stock units, Incentive Stock Program, change in control, Grant, award, or other acquisition, +1 more

5 terms

restricted stock units financial

"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Incentive Stock Program financial

"awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program")"

change in control financial

"on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock, $0.01 par value financial

"security_title: Common Stock, $0.01 par value"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AbbVie (ABBV) director Frederick H. Waddell report?

Frederick H. Waddell reported receiving 1,118 restricted stock units of AbbVie common stock as an equity award. These units were granted at no cash cost under AbbVie’s 2013 Incentive Stock Program as part of his compensation for board service.

How many AbbVie (ABBV) shares does Frederick H. Waddell hold after this Form 4?

After this transaction, Frederick H. Waddell directly holds 30,076 AbbVie common shares. This total includes the newly granted 1,118 restricted stock units, which will eventually settle into an equal number of shares when the specified payout conditions are met.

What are the terms of the restricted stock units granted to AbbVie (ABBV) director Waddell?

The 1,118 restricted stock units will be paid in AbbVie shares on a one-to-one basis. Payment occurs on the earlier of Waddell’s separation from service, his death, or a change in control, as defined under AbbVie’s Amended and Restated 2013 Incentive Stock Program.

Was cash involved in Frederick H. Waddell’s AbbVie (ABBV) Form 4 transaction?

No cash changed hands in this transaction. The Form 4 shows an equity award coded as “A,” indicating a grant or other acquisition, with a price per share of 0.0000, typical for restricted stock unit grants made as part of director compensation.

Does the AbbVie (ABBV) Form 4 show any stock sales by Frederick H. Waddell?

The Form 4 does not report any stock sales by Frederick H. Waddell. It only shows an acquisition of 1,118 restricted stock units as a grant, with no corresponding dispositions or open-market sales disclosed in this particular filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WADDELL FREDERICK H

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	05/08/2026		A		1,118(1)	A	$0	30,076	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

	/s/ T.O. Odutayo, Attorney-in-Fact for Frederick H. Waddell	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)